Chenodeoxycholic acid
- Generic Name
- Chenodeoxycholic acid
- Brand Names
- Chenodal, Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40O4
- CAS Number
- 474-25-9
- Unique Ingredient Identifier
- 0GEI24LG0J
- Background
Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can ...
- Indication
Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones.
- Associated Conditions
- Radiolucent Cholesterol gallstones
- Associated Therapies
- -
A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
- Conditions
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Leadiant Biosciences, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06260748
- Locations
- 🇮🇱
Sheba Medical Center, Tel HaShomer, Israel
Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)
- Conditions
- Interventions
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Humanis Saglık Anonim Sirketi
- Target Recruit Count
- 24
- Registration Number
- NCT06180057
- Locations
- 🇯🇴
ACDIMA Biocenter, Amman, Jordan
Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
- Conditions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Leadiant Biosciences Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05499026
Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT03168555
- Locations
- 🇩🇰
Zealand University Hospital, Køge, Denmark
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02952963
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, DK, Denmark
Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02876484
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass
- Conditions
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT02340247
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Effect of Bile Acids on GLP-1 Secretion
- Conditions
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 20
- Registration Number
- NCT01666223
- Locations
- 🇩🇰
Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Copenhagen, Denmark
Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism
- Conditions
- Interventions
- First Posted Date
- 2007-04-25
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 30
- Registration Number
- NCT00465751
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
Cholestanol in Humans
- Conditions
- Interventions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018694
- Locations
- 🇺🇸
VA New Jersey Health Care System, East Orange, East Orange, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.